Thus, systemic inflammation has been proposed as a mechanism in the development of muscle dysfunction in COPD patients as interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNF-α) have been shown to be elevated in these patients [6]. This evidence concerns the gene IL1B and chronic obstructive pulmonary disease.